Capricor Investors Urged to Contact Law Firm Over Securities Claims
News related to:Capricor Therapeutics, Inc · 1 min read
Faruqi & Faruqi, LLP, a leading national securities law firm, is reminding investors who purchased Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025, and July 26, 2026, of an important deadline. Investors are urged to contact the firm directly to discuss their legal rights.
The firm is investigating potential claims against Capricor Therapeutics, Inc., and is particularly concerned with statements and omissions related to the Company's clinical data and regulatory prospects for Deramiocel, a therapy for Duchenne muscular dystrophy. According to the complaint, Capricor failed to disclose that it had changed the pre-specified statistical analysis plan used to analyze Deramiocel's clinical data without first obtaining FDA approval. This omission, the firm argues, created a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of Deramiocel's effectiveness.
On July 27, 2026, the FDA released briefing documents stating that the "benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness." This news caused Capricor's stock to fall 64%, closing at $7.00 per share on unusually heavy trading volume. Two days later, on July 29, 2026, the FDA's Advisory Committee met, and in a non-binding 9-3 vote, concluded that the available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy. This decision led to a further 36% drop in the stock, closing at $4.19 per share on July 30, 2026.
Faruqi & Faruqi, LLP, is urging investors who suffered losses as a result of these events to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm is also encouraging anyone with information regarding Capricor's conduct to come forward.
The firm notes that the case is a federal securities class action and that any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice. The deadline for seeking the role of lead plaintiff is September 28, 2026.